Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good

  • Dynavax Technologies' stock has dropped 25% since my last 'Hold' rating in February 2025. The company's HEPLISAV-B continues to grow at significant rates. DVAX has ample liquidity supporting a balanced capital allocation program.